DefenCath® (taurolidine and heparin) catheter lock solution is indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis (HD) through a central venous catheter (CVC). This drug is indicated for use in a limited and specific population of patients.

Liz Hurlburt

Liz Masson Hurlburt serves as our EVP, Chief Clinical Strategy and Operations Officer. Prior to that, she held several progressive management roles in clinical operations, most recently at Gemphire Therapeutics, as Vice President, Clinical Operations. Responsible for strategic and clinical development activities, Liz has a passion for growing and developing highly engaged teams and assuring the highest standards for medical affairs and clinical development execution. Liz received her B.A. in Leadership and Organizational Management from Bay Path College and a Master’s in Management and Leadership from Western Governors University.